1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Innovent Biologics, Inc.

Innovent Biologics, Inc.

1801.HK
Innovent Biologics, Inc.HK flagHong Kong Stock Exchange
76.45
HKD
+3.50
- -
132.61BMarket Cap
Innovent Biologics, Inc.
1801.HK
(Hong Kong Stock Exchange)

Recent

price

76.45

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
0.02
0.03
0.89
2.83
2.93
3.06
3.98
5.79
7.77
Revenue per Share
-0.45
-0.5
-17.24
-1.46
-0.74
-1.87
-1.46
-0.66
-0.06
0.48
Basic EPS, GAAP
-0.38
-0.52
-3.96
-1.72
-0.8
-2.66
-2.21
-0.79
-0.26
5.55
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
-9.89
-10.11
-9.77
-9
Book Value per Share
-0.91
-1.5
12.37
4.04
6.45
6.57
6.4
7.04
7.05
10.42
Tangible Book Value per Share
1,118
1,118
335
1,178
1,357
1,456
1,490
1,560
1,627
1,677
Basic Weighted Avg Shares
- -
19
9
1,048
3,844
4,270
4,556
6,206
9,422
13,042
Sales/Revenue/Turnover
- -
-3,369.99
-16,382.83
-122.05
-1.1
-45.42
-56.67
-14.65
2.74
16.42
Operating Margin (%)
55
61
64
86
86
205
319
385
420
601
Depreciation Expense
-504
-562
-5,771
-1,720
-998
-2,729
-2,179
-1,028
-95
814
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.02
Effective Tax Rate (%)
- -
-3,033.33
-60,899.99
-164.19
-25.97
-63.91
-47.83
-16.56
-1
6.24
Profit Margin (%)
1,795
1,282
4,016
4,412
7,981
8,501
8,008
8,951
5,904
13,627
Working Capital
500
505
782
833
935
2,110
2,314
2,400
2,417
2,016
LT Debt
-958
-1,622
4,194
4,756
8,780
10,330
10,730
12,528
13,118
19,356
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
10.82
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-7.03
Return on Capital (%)
- -
-8,033,114.29
-13,267,797.7
-2,072,228.92
-1,085,240.22
-2,756,318.18
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
18.11%
47.56%
Free Cash Flow
- -
-442.36%
-2,327.06%
Net Income, GAAP
- -
-190.03%
-959.72%
Sales/Revenue/Turnover
- -
28.85%
38.42%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
6,206
2024
- -
- -
- -
- -
9,422
2025
- -
- -
- -
- -
13,042

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.66
2024
- -
- -
- -
- -
-0.06
2025
- -
- -
- -
- -
0.48

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Vaxcyte, Inc. (PCVX)
Celularity Inc. (CELU)
Feng Chi Biotech Corp. (6744.TWO)
Acer Therapeutics Inc. (ACER)
Tissue Regenix Group plc (TSSNF)
Sol-Gel Technologies Ltd. (SLGL)
Business